Unknown

Dataset Information

0

Insights into CD47/SIRPα axis-targeting tumor immunotherapy.


ABSTRACT: During the last decade, inhibitors targeting immune checkpoint programmed death ligand 1/PD-1 and cytotoxic T-lymphocyte-associated protein 4 have been one of the most significant advances for cancer therapy in clinic. However, most of these therapies focused on stimulating the adaptive immune system-mediated elimination of tumor. Recent studies indicated that CD47/Signal-regulatory protein alpha (SIRPα), an innate anti-phagocytic axis between cancer cells and macrophages, could be a promising therapeutic target. Here, we review the current knowledge about developing CD47/SIRPα checkpoint inhibitors, avoiding potential side effect and designing optimal combination therapies, and highlight the key points for future clinical applications of CD47/SIRPα axis-targeted tumor immunotherapy.

SUBMITTER: Zhang X 

PROVIDER: S-EPMC8157794 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9969460 | biostudies-literature
| S-EPMC8699673 | biostudies-literature
| S-EPMC9927946 | biostudies-literature
| S-EPMC9280883 | biostudies-literature
| S-EPMC7025889 | biostudies-literature
| S-EPMC9026896 | biostudies-literature
| S-EPMC6338872 | biostudies-literature
| S-EPMC6259379 | biostudies-literature
2024-06-04 | GSE235113 | GEO
| S-EPMC8557524 | biostudies-literature